An atlas of the bone marrow bone proteome in patients with dysproteinemias.


Journal

Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035

Informations de publication

Date de publication:
23 Jan 2023
Historique:
entrez: 7 2 2023
pubmed: 8 2 2023
medline: 8 2 2023
Statut: epublish

Résumé

Multiple myeloma (MM) bone disease is a significant cause of morbidity but there is a paucity of data on the impact of malignant plasma cells on adjacent trabecular bone within the BM. Here, we characterize the proteome of trabecular bone tissue from BM biopsies of 56 patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering (SMM), newly diagnosed (NDMM), relapsed MM (RMM), and normal controls. Proteins involved in extracellular matrix (ECM) formation and immunity pathways were decreased in SMM and active MM. Among the proteins most decreased were immunoglobulins, type IV collagen, and TIMP3, suggesting increased immunoparesis and decreased ECM remodelling within trabecular bone. Proteins most increased in SMM/MM were APP (enhances osteoclast activity), ENPP1 (enhances bone mineralization), and MZB1 (required for normal plasmablast differentiation). Pathway analyses showed that proteins involved in gamma -carboxylation, a pathway implicated in osteocalcin function, osteoblast differentiation, and normal hematopoiesis, were also overexpressed in SMM/MM. This study is the first comprehensive proteomic atlas of the BM bone proteome in dysproteinemias. We identify new key proteins and pathways for MM bone disease and potentially impaired hematopoiesis, and show for the first time that gamma -carboxylation pathways are increased in the bone tissue of SMM/MM.

Identifiants

pubmed: 36747663
doi: 10.21203/rs.3.rs-2468383/v1
pmc: PMC9900982
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NCI NIH HHS
ID : P50 CA186781
Pays : United States

Commentaires et corrections

Type : UpdateIn

Références

Clin Proteomics. 2021 Oct 12;18(1):24
pubmed: 34641785
Cancer Res. 2021 May 1;81(9):2415-2428
pubmed: 33526510
Nucleic Acids Res. 2019 Jul 2;47(W1):W199-W205
pubmed: 31114916
Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):E9630-E9639
pubmed: 30257949
Genome Biol. 2010;11(3):R25
pubmed: 20196867
Blood. 2019 Jul 18;134(3):227-238
pubmed: 31003999
Bone. 2014 Apr;61:164-75
pubmed: 24473375
BMC Genomics. 2014 Oct 17;15:904
pubmed: 25322877
Eur J Biochem. 1999 Oct;265(2):763-70
pubmed: 10504408
Sci Rep. 2017 Dec 19;7(1):17867
pubmed: 29259245
J Proteome Res. 2021 May 7;20(5):2533-2546
pubmed: 33683123
Front Behav Neurosci. 2016 Mar 11;10:46
pubmed: 27014007
Leukemia. 2017 Nov;31(11):2426-2434
pubmed: 28344315
BMB Rep. 2014 Mar;47(3):141-8
pubmed: 24499667
J Biol Chem. 2000 Oct 6;275(40):31226-32
pubmed: 10900194
Cancers (Basel). 2021 Jan 09;13(2):
pubmed: 33435306
Front Pharmacol. 2020 May 26;11:757
pubmed: 32528290
J Biomech Eng. 2015 Jan;137(1):
pubmed: 25412137
FASEB J. 2020 Apr;34(4):5483-5498
pubmed: 32107793
Front Oncol. 2021 Feb 09;10:625199
pubmed: 33634031
Clin Lymphoma Myeloma Leuk. 2020 Oct;20(10):e752-e768
pubmed: 32651110
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Br J Haematol. 1998 Jun;101(4):694-702
pubmed: 9674743
Arch Pharm Res. 2011 Aug;34(8):1381-7
pubmed: 21910061
Nat Protoc. 2016 Dec;11(12):2301-2319
pubmed: 27809316
Oncotarget. 2015 Aug 21;6(24):19924-5
pubmed: 26343369
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
Calcif Tissue Int. 2017 Jun;100(6):631-640
pubmed: 28236102
J Biol Chem. 1994 Mar 25;269(12):9352-60
pubmed: 8132674
Blood Cancer J. 2021 Mar 1;11(3):45
pubmed: 33649314

Auteurs

Classifications MeSH